Peptide Profile
KPV Tripeptide
KPV is a synthetic C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone ($\alpha$-MSH, specifically residues 11–13). It retains the potent anti-inflammatory and antimicrobial properties of the full-length $\alpha$-MSH hormone.
1. Chemical Structure and Biochemistry
KPV is one of the smallest bioactive peptide fragments in immunology research.
- Peptide Sequence: Lys-Pro-Val (L-Lysyl-L-Prolyl-L-Valine)
- Size & Stability: Due to its low molecular weight (~342 Da) and three-amino-acid structure, it demonstrates strong stability and is capable of entering cells directly via the PepT1 peptide transporter, particularly in intestinal epithelial cells.
2. Mechanism of Action
Unlike full $\alpha$-MSH, KPV exerts its primary effects intracellularly rather than relying solely on melanocortin receptor (MC1R) activation.
- NF-$\kappa$B Inhibition: Once inside the cell, KPV translocates to the nucleus and inhibits the activation of NF-$\kappa$B, a master transcription factor that drives the expression of pro-inflammatory cytokines (such as IL-1$\beta$, IL-6, and TNF-$\alpha$).
- Antimicrobial Activity: Demonstrates direct bacteriostatic and fungistatic activity against pathogens such as Staphylococcus aureus and Candida albicans in vitro.
3. Research and Applications
Because it suppresses inflammation without causing systemic immunosuppression or skin darkening, KPV is researched across gastroenterology and dermatology.
- Inflammatory Bowel Disease (IBD): Extensively studied in preclinical models of ulcerative colitis and Crohn's disease for reducing mucosal inflammation and accelerating epithelial healing.
- Dermatology & Wound Healing: Investigated for treating psoriasis, eczema, allergic contact dermatitis, and reducing scar formation during wound repair.
Tags:
KPV
KPV-tripeptide
Lys-Pro-Val
alpha-MSH-11-13
anti-inflammatory-peptide
NF-kB-inhibitor
PepT1
IBD-research
colitis
wound-healing
antimicrobial-peptide